Search
Isoxicam
go.drugbank.com/drugs/DB08942ApprovedWithdrawnIsoxicam is a non-steroidal anti-inflammatory drug that is not marketed in the United States.
Categories: Non COX-2 selective NSAIDS, Heterocyclic Compounds, 1-RingIndenolol
go.drugbank.com/drugs/DB08952ApprovedWithdrawnIndenolol is a drug of the beta-adrenergic blocker class.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesFendiline
go.drugbank.com/drugs/DB08980ApprovedWithdrawnFendiline is non-selective. … Fendiline is a coronary vasodilator which inhibits calcium function in muscle cells in excitation-contraction coupling. It has been proposed as an antiarrhythmic and antianginal agent.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: SENSIT FEnviomycin
go.drugbank.com/drugs/DB08993ExperimentalIt is isolated from an induced mutant of Streptomyces griseoverticillatus var. tuberacticus and acts as an antitubercular agent with less ototoxicity than tuberactinomycin.
Synonyms: Tuberactinomycin NDexetimide
go.drugbank.com/drugs/DB08997ApprovedWithdrawnA muscarinic antagonist that has been used to treat neuroleptic-induced parkinsonism. Benzetimide is the (-)-enantimorph of dexetimide.
Categories: Heterocyclic Compounds, 1-RingDemexiptiline
go.drugbank.com/drugs/DB08998ExperimentalDemexiptiline is marketed under the names Deparon or Tinoran. It is a tricyclic antidepressant which acts primarily as a norepinephrine reuptake inhibitor.
Carmofur
go.drugbank.com/drugs/DB09010ApprovedWithdrawnCarmofur is a derivative of fluorouracil, and is an antineoplastic agent that has been used in the treatment of breast and colorectal cancer. Carmofur has been known to induce leukoencephalopathy.
Categories: Heterocyclic Compounds, 1-RingBromopride
go.drugbank.com/drugs/DB09018InvestigationalBromopride is a dopamine antagonist used as an antiemetic. Its prokinetic properties are similar to those of metoclopramide. It is unavailable in America or the United Kingdom.
Synonyms: 4-amino-5-bromo-N-[2-(diethylamino)ethyl]-2-methoxybenzamideMixtures: ENZYMED®TABLETAS RECUBIERTASVedolizumab
go.drugbank.com/drugs/DB09033ApprovedInvestigational[A261576] Vedolizumab is administered by IV infusion over a period of 30 minutes; after the first dose, it is given again at two and six weeks and then every 8 weeks thereafter. … Vedolizumab is a recombinant humanized IgG1 monoclonal antibody directed against the human lymphocyte α4β7 integrin, a key mediator of gastrointestinal inflammation implicated in diseases like ulcerative
Products: ENTYVIO SC, ENTYVIO® 108 MG SOLUCIÓN INYECTABLE